Published in J Natl Cancer Inst on August 21, 1991
Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst (2009) 4.36
Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br J Cancer (2003) 1.12
A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. CPT-11 Lung Cancer Study Group. Br J Cancer (1998) 1.02
Dose-finding study of irinotecan and cisplatin plus concurrent radiotherapy for unresectable stage III non-small-cell lung cancer [seecomments]. Br J Cancer (1998) 0.97
Complete response of highly advanced colon cancer with multiple lymph node metastases to irinotecan combined with UFT: report of a case. Surg Today (2006) 0.93
Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer. Br J Cancer (1993) 0.93
Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens. J Pharmacol Exp Ther (2013) 0.91
Current perspectives on camptothecins in cancer treatment. Br J Cancer (1996) 0.90
Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer. Br J Clin Pharmacol (2005) 0.90
In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors. J Clin Invest (1998) 0.87
Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer. Br J Cancer (1999) 0.87
Fractionated administration of irinotecan and cisplatin for treatment of non-small-cell lung cancer: a phase II study of Okayama Lung Cancer Study Group. Br J Cancer (2001) 0.86
hMSC-mediated concurrent delivery of endostatin and carboxylesterase to mouse xenografts suppresses glioma initiation and recurrence. Mol Ther (2011) 0.85
A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer. Br J Clin Pharmacol (1999) 0.84
Pharmacogenetics of irinotecan: a promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecan. Invest New Drugs (2005) 0.83
Progress in treatment of small-cell lung cancer: role of CPT-11. Br J Cancer (2003) 0.83
Concomitant polypharmacy is associated with irinotecan-related adverse drug reactions in patients with cancer. Int J Clin Oncol (2012) 0.80
Clinical, pharmacokinetic and biological studies of topotecan. Cancer Chemother Pharmacol (1994) 0.79
Preclinical antitumor activity of a nanoparticulate SN38. Invest New Drugs (2013) 0.79
Clinical studies of irinotecan alone and in combination with cisplatin. Cancer Chemother Pharmacol (1994) 0.78
7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials. Cancer Chemother Pharmacol (1994) 0.77
Phase II study of protracted irinotecan infusion and a low-dose cisplatin for metastatic gastric cancer. World J Gastroenterol (2006) 0.77
Smac mimetic LCL161 supports neuroblastoma chemotherapy in a drug class-dependent manner and synergistically interacts with ALK inhibitor TAE684 in cells with ALK mutation F1174L. Oncotarget (2016) 0.76
Phase I study of irinotecan for previously treated lung cancer patients with the UGT1A1*28 or *6 polymorphism: Results of the Lung Oncology Group in Kyushu (LOGIK1004A). Thorac Cancer (2016) 0.75
A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature (2000) 6.01
Aphidicolin prevents mitotic cell division by interfering with the activity of DNA polymerase-alpha. Nature (1978) 5.91
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol (1999) 5.65
AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci U S A (1992) 5.24
Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J (2009) 4.63
Repression domains of class II ERF transcriptional repressors share an essential motif for active repression. Plant Cell (2001) 4.19
The dinB gene encodes a novel E. coli DNA polymerase, DNA pol IV, involved in mutagenesis. Mol Cell (1999) 4.01
Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer (1998) 3.81
Multiple pathways for SOS-induced mutagenesis in Escherichia coli: an overexpression of dinB/dinP results in strongly enhancing mutagenesis in the absence of any exogenous treatment to damage DNA. Proc Natl Acad Sci U S A (1997) 3.53
Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus. J Neurosci (1997) 3.49
Tbx5 associates with Nkx2-5 and synergistically promotes cardiomyocyte differentiation. Nat Genet (2001) 3.14
Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization. J Clin Invest (2000) 2.96
One subspecies of the red junglefowl (Gallus gallus gallus) suffices as the matriarchic ancestor of all domestic breeds. Proc Natl Acad Sci U S A (1994) 2.64
Molecular basis for resistance to silver cations in Salmonella. Nat Med (1999) 2.62
A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol (1992) 2.58
Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis. Am J Pathol (1997) 2.55
Noninvasive assessment of bone mineral and structure: state of the art. J Bone Miner Res (1996) 2.47
Oxidative stress activates extracellular signal-regulated kinases through Src and Ras in cultured cardiac myocytes of neonatal rats. J Clin Invest (1997) 2.44
Takayasu's arteritis. Clinical report of eighty-four cases and immunological studies of seven cases. Circulation (1967) 2.42
Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol (2012) 2.38
Intact motility as a Salmonella typhi invasion-related factor. Infect Immun (1988) 2.32
Roles of chromosomal and episomal dinB genes encoding DNA pol IV in targeted and untargeted mutagenesis in Escherichia coli. Mol Genet Genomics (2001) 2.31
Monophyletic origin and unique dispersal patterns of domestic fowls. Proc Natl Acad Sci U S A (1996) 2.27
Structural and functional characterization of inositol 1,4,5-trisphosphate receptor channel from mouse cerebellum. J Biol Chem (1991) 2.23
Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br J Cancer (2008) 2.19
Aggressive natural killer cell leukaemia/lymphoma: report of four cases and review of the literature. Possible existence of a new clinical entity originating from the third lineage of lymphoid cells. Br J Haematol (1990) 2.18
A genome-wide association study identifies an association of a common variant in TERT with susceptibility to idiopathic pulmonary fibrosis. J Med Genet (2008) 2.15
Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel. Ann Oncol (2009) 2.14
Follow-up study after intracranial percutaneous transluminal cerebral balloon angioplasty. AJNR Am J Neuroradiol (1998) 2.12
Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer. Int J Clin Oncol (2001) 2.10
Comparisons of noninvasive bone mineral measurements in assessing age-related loss, fracture discrimination, and diagnostic classification. J Bone Miner Res (1997) 2.09
Idiopathic nonspecific interstitial pneumonia: prognostic significance of cellular and fibrosing patterns: survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia. Am J Surg Pathol (2000) 2.07
The proteins encoded by c-akt and v-akt differ in post-translational modification, subcellular localization and oncogenic potential. Oncogene (1993) 2.05
Pressure overload induces cardiac hypertrophy in angiotensin II type 1A receptor knockout mice. Circulation (1998) 2.05
Calcineurin plays a critical role in the development of pressure overload-induced cardiac hypertrophy. Circulation (2001) 2.04
Use of the AO hook-plate for treatment of unstable fractures of the distal clavicle. Arch Orthop Trauma Surg (2007) 2.03
A prospective phase II study on photodynamic therapy with photofrin II for centrally located early-stage lung cancer. The Japan Lung Cancer Photodynamic Therapy Study Group. J Clin Oncol (1993) 2.02
Intraoral minor salivary gland tumors: a clinicopathological study of 82 cases. Int J Oral Maxillofac Surg (2005) 2.02
Aphidicolin: a specific inhibitor of DNA polymerases in the cytosol of rat liver. Biochem Biophys Res Commun (1978) 2.02
A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection. J Nucl Med (1980) 2.01
Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res (1993) 2.01
T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Cancer Res (1993) 1.98
Massive proteinuria induced in rats by a single intravenous injection of a monoclonal antibody. J Immunol (1988) 1.96
Ultrastructural basis of experimental thrombocytopenic purpura. Arch Pathol (1970) 1.95
Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. Br J Cancer (2000) 1.93
Bone morphogenetic proteins induce cardiomyocyte differentiation through the mitogen-activated protein kinase kinase kinase TAK1 and cardiac transcription factors Csx/Nkx-2.5 and GATA-4. Mol Cell Biol (1999) 1.91
Inheritance of chromosomally integrated human herpesvirus 6 DNA. Blood (1999) 1.90
IFN-gamma-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones. J Immunol (1996) 1.85
Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25). Blood (1999) 1.84
Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer (2001) 1.81
A gene (sleB) encoding a spore cortex-lytic enzyme from Bacillus subtilis and response of the enzyme to L-alanine-mediated germination. J Bacteriol (1996) 1.79
Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res (1999) 1.76
An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study Group. Oncology (1999) 1.75
Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol (2003) 1.75
Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc Natl Acad Sci U S A (1987) 1.72
Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy. Kidney Int (2000) 1.72
Simple genetic method to identify viridans group streptococci by colorimetric dot hybridization and fluorometric hybridization in microdilution wells. J Clin Microbiol (1988) 1.68
Caspase-1-independent, Fas/Fas ligand-mediated IL-18 secretion from macrophages causes acute liver injury in mice. Immunity (1999) 1.67
Synthesis and alpha-D-glucosidase inhibitory activity of N-substituted valiolamine derivatives as potential oral antidiabetic agents. J Med Chem (1986) 1.67
A germination-specific spore cortex-lytic enzyme from Bacillus cereus spores: cloning and sequencing of the gene and molecular characterization of the enzyme. J Bacteriol (1996) 1.65
Interstitial lung disease associated with drug therapy. Br J Cancer (2004) 1.64
Chromosomal transmission of human herpesvirus 6 DNA in acute lymphoblastic leukaemia. Lancet (1998) 1.64
Serological diagnosis of idiopathic pulmonary alveolar proteinosis. Am J Respir Crit Care Med (2000) 1.63
IL-18 accounts for both TNF-alpha- and Fas ligand-mediated hepatotoxic pathways in endotoxin-induced liver injury in mice. J Immunol (1997) 1.62
Increase in susceptibility of Pseudomonas aeruginosa to carbapenem antibiotics in low-amino-acid media. Antimicrob Agents Chemother (1991) 1.61
Endothelin-1 is involved in mechanical stress-induced cardiomyocyte hypertrophy. J Biol Chem (1996) 1.57
CD28-b7 blockade in organ dysfunction secondary to cold ischemia/reperfusion injury. Kidney Int (1997) 1.57
Macular buckling for retinal detachment due to macular hole in highly myopic eyes with posterior staphyloma. Retina (2000) 1.57
Survivin expression in tumor cell nuclei is predictive of a favorable prognosis in gastric cancer patients. Cancer Lett (2001) 1.56
Lysis of Streptococcus mutans cells with mutanolysin, a lytic enzyme prepared from a culture liquor of Streptomyces globisporus 1829. Arch Oral Biol (1978) 1.56
Dual somatotopical representations in the primate subthalamic nucleus: evidence for ordered but reversed body-map transformations from the primary motor cortex and the supplementary motor area. J Neurosci (1996) 1.56
Myocardial emission computed tomography with iodine-123-labeled beta-methyl-branched fatty acid in patients with hypertrophic cardiomyopathy. J Nucl Med (1992) 1.55
Intravenous immunoglobulin therapy for diabetic amyotrophy. Intern Med (2001) 1.55
Cervical laminoplasty (Hattori's method). Procedure and follow-up results. Spine (Phila Pa 1976) (1988) 1.55
Epidemiology of sarcoidosis in Japan. Eur Respir J (2007) 1.54
[Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group]. Gan To Kagaku Ryoho (1994) 1.54
Corticostriatal and corticosubthalamic input zones from the presupplementary motor area in the macaque monkey: comparison with the input zones from the supplementary motor area. Brain Res (1999) 1.54
A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer. Ann Oncol (2011) 1.54
Protein kinase C, but not tyrosine kinases or Ras, plays a critical role in angiotensin II-induced activation of Raf-1 kinase and extracellular signal-regulated protein kinases in cardiac myocytes. J Biol Chem (1996) 1.53
Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann Oncol (2001) 1.52
Localization of matrix metalloproteinases-1, -2, and -9 and tissue inhibitor of metalloproteinase-2 in interstitial lung diseases. Lab Invest (1998) 1.51
CT is useful for identifying patients with complicated appendicitis. Dig Liver Dis (2004) 1.50
Structure, expression and chromosomal mapping of c-akt: relationship to v-akt and its implications. Oncogene (1993) 1.49
[Clinical effects of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis]. Nihon Kyobu Shikkan Gakkai Zasshi (1987) 1.48
Targeted disruption of Na+/Ca2+ exchanger gene leads to cardiomyocyte apoptosis and defects in heartbeat. J Biol Chem (2000) 1.48
MR imaging of perinatal brain damage: comparison of clinical outcome with initial and follow-up MR findings. AJNR Am J Neuroradiol (1999) 1.48
IL-18 up-regulates perforin-mediated NK activity without increasing perforin messenger RNA expression by binding to constitutively expressed IL-18 receptor. J Immunol (1999) 1.48
Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance. Ann Oncol (2004) 1.48
Decreased circulating adrenomedullin in pre-eclampsia. Lancet (1997) 1.48
Analysis of mtDNA sequences shows Japanese native chickens have multiple origins. Anim Genet (2007) 1.47